

# QUARTERLY REPORTS

**Compiled:** as at 31 December 2018

**For:** MARC 14 March 2019

[REDACTED]

# CONTENTS

Reporting period covered: 4<sup>th</sup> Quarter 2018

01 October 2018 to 31 December 2018

## Section 1: Overview

[Table 1]	Summary of medicine related reports – reporter type and seriousness	1
[Table 2]	Summary of vaccine related reports – reporter type and seriousness	1

## Section 2: Potential Safety Signals

[Table 3]	Safety Signals from Single case reports (No report this quarter)	3
[Table 4]	Safety Signals from Reporting trends (No report this quarter)	3

## Section 3: Review of Fatal Cases

[Table 5]	Fatal cases assessed causal	4
-----------	-----------------------------	---

## Section 4: Special Populations

[Table 6]	Serious cases associated with medicines in patients under 18 years	5
[Table 7]	Serious cases of serious AEFI terms with vaccines in patients under 18 years	8
[Table 8]	Serious cases of critical terms in patients over 80 years	12
[Table 9]	Causal and Serious cases in patients 18 to 80 years	15

## Section 5: Special Reports

Nil



## Section 1: Overview

Period of Report: 01 October 2018 to 31 December 2018  
 Number of Reports received: 1143

**Table 1: Summary of medicine related reports [n=828]**

Description	Fatal	Other Serious*	Non-serious*	Total
General Practitioners		13	98	111
Hospital Doctors	1	54	82	137
Hospital Pharmacists	1	30	30	61
Community Pharmacists		2	44	46
Nurses	1	7	78	86
Other HC professionals		2	20	22
Pharmaceutical Company	10	46	62	118
Coroner				0
ACC				0
Public		89	149	238
Other			9	9
<b>Total</b>	<b>13</b>	<b>243*</b>	<b>572*</b>	<b>828</b>


**Table 2: Summary of vaccine related reports [n=315]**

Description	Fatal	Other Serious*	Non-serious*	Total
General Practitioners		3	39	42
Hospital Doctors		2	5	7
Hospital Pharmacists			1	1
Community Pharmacists			1	1
Nurses	1	7	238	246
Other HC professionals				0
Pharmaceutical Company		1	2	3
Coroner				0
ACC				0
Public		1	9	10
Other			5	5
<b>Total</b>	<b>1</b>	<b>14</b>	<b>300</b>	<b>315</b>

\* Seriousness is assessed for each report based on the 'result of the adverse reaction(s)'

- Patient Died
- Congenital abnormality
- Patient hospitalisation or prolonged hospitalisation
- Reaction was Life Threatening
- Intervention was required to avoid permanent disability
- Persisting disability

## Overview of Reporting



**Figure 1:** Comparison of Reporters – percentage of reports per Quarter

Note: The increased percentage of “Others” in the 2018-Q3 and 2018-Q4 periods reflects the increased number of cases received from the Public

**Section 2: Presentation of Potential Safety Signals**

**Table 3: Single Case Reports**

*No reports requiring discussion of regulatory action this quarter*

**Table 4: Safety Signals from Reporting Trends**

*No trends requiring discussion of regulatory action this quarter*

Section 3: Review of Fatal Cases

**Table 5: Fatal Cases assessed causal - October to December 2018**

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity/OUTCOME
130309	[REDACTED]	OCT2018	EMBOLISM CEREBRAL THROMBOSIS	* DABIGATRAN	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	75	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
130578	[REDACTED]	OCT2018	TOXIC EPIDERMAL NECROLYSIS	* FLUCONAZOLE CLOTRIMAZOLE	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	72	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
130251	[REDACTED]	OCT2018	AGRANULOCYTOSIS	* MIRTAZAPINE * CORTICOSTEROIDS UNCLASSIFIED THIAMINE MELATONIN MULTIVITE	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	89	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Section 4: Review of Cases in Special Populations (Children and Elderly)

**Table 6: Serious cases causally associated with medicines in children under 18 years**

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130764	[REDACTED]	NOV2018	FEVER SEPSIS TACHYCARDIA NEUTROPENIA	* INTRAGAM P * PREDNISOLONE * MERCAPTOPURINE * METHOTREXATE	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	5	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
131292	[REDACTED]	DEC2018	ANAPHYLACTIC REACTION	* IBUPROFEN * AMOXICILLIN/CLAVULANIC ACID	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	9	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
131294	[REDACTED]	DEC2018	ANAPHYLACTIC REACTION	* IBUPROFEN FLUTICASONE/SALMETEROL	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	3	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Serious Cases in Patients under 18 ...continued

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130579	[REDACTED]	OCT2018	RASH OEDEMA PERIORBITAL FEELING UNWELL BRONCHOSPASM TONGUE SWELLING NON-SPECIFIC	* AMOXICILLIN	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	2m	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
130426	[REDACTED]	OCT2018	RASH OEDEMA PERIORBITAL BRONCHOSPASM PRURITUS	* FLUCLOXACILLIN	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	9m	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
130548	[REDACTED]	OCT2018	RASH MACULO-PAPULAR VOMITING	* FLUCLOXACILLIN	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	12m	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
130626	[REDACTED]	OCT2018	NEUTROPENIA FEVER ABDOMINAL PAIN RASH HEPATIC ENZYMES INCREASED	* MEROPENEM	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	12	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]



Serious Cases in Patients under 18 ...continued

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130693	[REDACTED]	NOV2018	ANAPHYLAXIS	* CEPHAZOLIN	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	10	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
130902	[REDACTED]	NOV2018	ANAPHYLACTIC REACTION SKIN TEST POSITIVE	* CEPHAZOLIN PROPOFOL ATRACURIUM	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	9	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
131306	[REDACTED]	DEC2018	ANAPHYLACTIC REACTION	* PEGASPARGASE	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	2	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

**Table 7: Serious cases reporting serious AEFI terms with vaccines in children Under 18 years**

REPORT	ORIGIN	DATE	Severe	REACTIONS	VACCINE	AGE	SEX	Ethnicity	OUTCOME
130365	[REDACTED]	OCT2018	[REDACTED]	APNOEA	* ROTA VIRUS VACCINE * DTaP-Hexa * PNEUMOCOCCAL VACC - 13	3m	M	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
130728	[REDACTED]	NOV2018	[REDACTED]	CONSCIOUSNESS DECREASED HHE	* ROTA VIRUS VACCINE * DTaP-Hexa * PNEUMOCOCCAL VACC - 10	1m	M	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
131189	[REDACTED]	DEC2018	[REDACTED]	FEVER CONVULSIONS	* DTaP-Hexa * PNEUMOCOCCAL VACC - 10	1m	F	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Serious Vaccine AEFI Cases in Patients under 18 ...continued

REPORT	ORIGIN	DATE	Severe	REACTIONS	VACCINE	AGE	SEX	Ethnicity	OUTCOME
130556	█	OCT2018	█	FEVER CONVULSIONS	HAEMOPHILUS B (HIBERIX) * MEASLES-MUMPS-RUBELLA VACCINE PNEUMOCOCCAL VACC - 10 * VARICELLA VIRUS VACCINE	15m	M	█	█
█	█	█							
█	█	█							
131300	█	DEC2018	█	ERYTHEMA OEDEMA PERIORBITAL COUGHING BRONCHOSPASM THROAT IRRITATION	* MENINGOCOCCAL ACYW135 ANTIBIOTICS UNCLASSIFIED	23m	M	█	█
█	█	█							
█	█	█							

## Serious AEFI Terms

System Organ Class	AEFI
Alimentary	PAROTID ENLARGEMENT
	PAROTITIS
Application Site	ISR ABCESS
	ISR INFLAMMATION (SEVERE)
	ISR ABSCESS STERILE
Endocrine/Metabolic	LARYNGOTRACHEAL OEDEMA
	LARYNX OEDEMA
	ORCHITIS
Haematological	THROMBOCYTOPENIA
Musculoskeletal	ARTHRALGIA
	ARTHRITIS
	ARTHROPATHY
	ARTHROSIS
	OSTEOMYELITIS
Nervous System	CONVULSIONS
	CONVULSIONS GRAND MAL
	ENCEPHALITIS
	ENCEPHALOMYELITIS
	ENCEPHALOPATHY
	FEVER CONVULSIONS
	GUILLAIN-BARRE SYNDROME
	HYPOTONIC-HYPORESPONSIVE EPISODE (HHE)
	MENINGITIS
	MENINGITIS ASEPTIC
	MENINGOENCEPHALITIS
	NEURITIS
	NEURITIS CRANIAL
	NEURITIS MOTOR
	NEURITIS SENSORY
	OEDEMA CEREBRAL
	PETIT MAL CONVULSION
POLIOMYELITIS	

## Serious AEFI Terms

System Organ Class	AEFI
Others	ALLERGIC REACTION
	ANAPHYLACTIC REACTION
	ANAPHYLACTIC SHOCK
	ANAPHYLACTOID REACTION
	ANAPHYLAXIS
	CRYING ABNORMAL
	DEATH
	FACE OEDEMA
	FEVER $\geq$ 40
	LYMPHADENOPATHY
	OEDEMA
	OEDEMA GENERALISED
	TONGUE OEDEMA
Resistance Mechanism Disorders	SEPSIS
	SEPTICAEMIA
	VACCINE FAILURE
Respiratory	APNOEA
	BRONCHOSPASM
	DYSPNOEA
	OEDEMA PULMONARY
Skin and Appendages	ABSCESS
	ACUTE GEN. ECZEMATOUS PUSTULOSIS
	ANGIOEDEMA
	ANGIOEUROTIC OEDEMA
	BULLOUS ERUPTION
	ECZEMA
	EPIDERMAL NECROLYSIS
	ERYTHEMA MULTIFORME
	PRURITUS
	STEVENS JOHNSON SYNDROME
	TOXIC EPIDERMAL NECROLYSIS
	URTICARIA

**Table 8: Serious non-fatal cases causally associated with critical terms in patients over 80 years**

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130385	[REDACTED]	OCT2018	INTERSTITIAL LUNG DISEASE	* AMIODARONE	[REDACTED]	[REDACTED]			85	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
130526	[REDACTED]	OCT2018	EPISTAXIS MELAENA	* RIVAROXABAN AMIODARONE SPIRONOLACTONE METOPROLOL ATORVASTATIN FUROSEMIDE RISEDRONATE	[REDACTED]	[REDACTED]			88	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
130207	[REDACTED]	OCT2018	EMBOLISM PULMONARY	* TRANEXAMIC ACID SIMVASTATIN METFORMIN CILAZAPRIL ACETYLSALICYLIC ACID	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	84	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
130873	[REDACTED]	NOV2018	ANAEMIA HAEMOLYTIC	* AMOXICILLIN/CLAVULANIC ACID	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	85	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Serious non-fatal cases in patients Over 80.....continued

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130932	[REDACTED]	NOV2018	STEVENS JOHNSON SYNDROME	* VANCOMYCIN * CEFTRIAXONE		[REDACTED]	[REDACTED]	[REDACTED]	87	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
130413	[REDACTED]	OCT2018	PHARYNGITIS AGRANULOCYTOSIS	* SULPHASALAZINE	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	81	F	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
130688	[REDACTED]	NOV2018	INTERSTITIAL LUNG DISEASE MEDICATION ERROR	* NITROFURANTOIN	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	84	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Serious non-fatal cases in patients Over 80.....continued

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130642	[REDACTED]	OCT2018	BONE MARROW DEPRESSION DIARRHOEA DEHYDRATION HYPOTENSION POSTURAL ASTHENIA	* LENALIDOMIDE DEXAMETHASONE	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	82	M	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]



**Table 9: Causal and Serious Cases in 18 to 80 age group**

181 cases have been assessed Causal and Serious  
200 suspect medicines involved

**Table 9.1: ATC classification Overview**

	<b>ATC High Level Group</b>	<b>No. of Medicines</b>	<b>Percentage</b>
<b>A</b>	Alimentary	8	4.0
<b>B</b>	Blood and Blood forming organs	7	3.5
<b>C</b>	Cardiovascular	4	2.0
<b>D</b>	Dermatological	3	1.5
<b>G</b>	Genito Urinary System and Sex Hormones	5	2.5
<b>H</b>	Systemic Hormones (excl Sex Hormones)	4	2.0
<b>J</b>	Anti-infectives	38	19.0
<b>L</b>	Antineoplastics and Immunomodulating Agents	9	4.5
<b>M</b>	Musculoskeletal	12	6.0
<b>N</b>	Nervous System	105	52.5
<b>P</b>	Antiparasitic Products, Insecticides and Repellents	0	
<b>R</b>	Respiratory System	2	1.0
<b>S</b>	Sensory Organs	0	
<b>V</b>	Miscellaneous	3	1.5
	<b><u>Total Suspect Medicines</u></b>	<b>200</b>	<b>100.0</b>

**Table 9.2: ATC Detailed listing of Medicines**

	<b>ATC Group</b>	<b>Number</b>	<b>Total</b>
<b>A</b>	<b>Alimentary</b>		<b>8</b>
A02B	Omeprazole	1	
	Pantoprazole	1	
A04A	Ondansetron hydrochloride	3	
A06A	Konsyl D	1	
A07D	Loperamide	1	
	Vildagliptin	1	
<b>B</b>	<b>Blood and Blood forming organs</b>		<b>7</b>
B01A	Alteplase	1	
	Dabigatran	3	
	Rivaroxaban	1	
	Ticagrelor	1	
B03A	Iron Carboxymaltose	1	
<b>C</b>	<b>Cardiovascular</b>		<b>4</b>
C05A	Proctosedyl	1	
C08D	Diltiazem	1	
C10A	Atorvastatin	1	
	Pravastatin	1	
<b>D</b>	<b>Dermatological</b>		<b>3</b>
D08A	Chlorhexidine	3	
<b>G</b>	<b>Genito Urinary System and Sex Hormones</b>		<b>5</b>
G03A	Levien ED	1	
	Mirena	2	
G03H	Cyproterone acetate	1	
G04C	Finasteride	1	
<b>H</b>	<b>Systemic Hormones (excl Sex Hormones)</b>		<b>4</b>
H02A	Prednisone	3	
	Triamcinolone	1	
<b>J</b>	<b>Anti-infectives</b>		<b>38</b>
J01C	Amoxicillin/Clavulanic Acid	7	
	Flucloxacillin	3	
	Piperacillin / Tazobactam	1	
J01D	Cefuroxime	1	
	Cephalexin	1	
	Cephazolin	11	
	Merepenem	1	
J01E	Cotrimoxazole	4	
	Trimethoprim	2	
J01M	Ciprofloxacin	1	
J01X	Nitrofurantoin	1	
	Teicoplanin	1	
	Vancomycin	1	
J04A	Isoniazid	1	
J07B	Influenza Trivalent	1	
	Varicella Vaccine - Shingles	1	

<b>L</b>	<b>Antineoplastics and Immunomodulating Agents</b>		<b>9</b>
L01X	Bendamustine	1	
	Fluorouracil	1	
	Methotrexate	1	
	Cetuximab	1	
	Rituximab	1	
L02B	Goserelin acetate	1	
L03A	BCG Immunotherapy	1	
L04A	Adalimumab	1	
	Natalizumab	1	
<b>M</b>	<b>Musculoskeletal</b>		<b>12</b>
M01A	Diclofenac	2	
	Ibuprofen	2	
	Naproxen	1	
M03A	Pancuronium	1	
	Rocuronium	1	
	Suxamethonium chloride	2	
M04A	Allopurinol	1	
M05B	Denosumab	1	
	Zoledronate	1	
<b>N</b>	<b>Nervous System</b>		<b>105</b>
N01A	Ketamine	1	
N01B	Bupivacaine	1	
	Lignocaine	1	
N02A	Oxycodone	1	
	Tramadol	1	
N02B	Acetylsalicylic acid	2	
	Paracetamol	2	
N03A	Carbamazepine	1	
	Gabapentin	1	
	Pregabalin	1	
N05A	Clozapine	5	
	Lithium carbonate	1	
	Olanzapine	3	
	Paliperidone	1	
N06A	Fluoxetine	1	
	Paroxetine	1	
	Sertraline	1	
	Venlafaxine	80	
<b>P</b>	<b>Antiparasitic Products, Insecticides &amp; Repellents</b>		<b>0</b>
<b>R</b>	<b>Respiratory</b>		<b>2</b>
R03D	Montelukast sodium	1	
R05F	Gees Linctus	1	
<b>S</b>	<b>Sensory Organs</b>		<b>0</b>
<b>V</b>	<b>Miscellaneous</b>		<b>3</b>
V04C	Patent Blue V	3	
	<b>Total Medicines</b>		<b>200</b>

**TABLE 9.3: Causal and Serious Cases in 18 to 80 age group**

Note: 200 suspect medicines (indicated by an asterisk) have been involved on 181 cases. Each case appears in the ATC group of the suspect medicine which is highlighted. Cases with multiple suspects appear multiple times and can be in more than one ATC group

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
<b>ATC = Alimentary</b>											
130580	██████	OCT2018	RASH PUSTULAR LIPS DRY LIPS SWELLING NON-SPECIFIC	* OMEPRAZOLE * DILTIAZEM DABIGATRAN	█	█████	█	█	80	F	█████
130692	██████	NOV2018	HEPATITIS NAUSEA JAUNDICE	* ISONIAZID * PANTOPRAZOLE CABERGOLINE PARACETAMOL PYRIDOXINE	█	█████	█	█	64	M	█████
130941	██████	NOV2018	URTICARIA ANGIOEDEMA SKIN TEST POSITIVE ANAPHYLACTIC REACTION	* ONDANSETRON HYDROCHLORIDE MIDAZOLAM PROPOFOL CEPHAZOLIN CHLORHEXIDINE	█	█████	█	█	59	F	█████
131132	██████	DEC2018	INFUSION SITE RASH	* ONDANSETRON HYDROCHLORIDE	█	█████	█	█	37	F	█████
131256	██████	DEC2018	RASH ERYTHEMATOUS PRURITUS OEDEMA PERIPHERAL TACHYCARDIA TACHYPNOEA	* CEFUROXIME * ONDANSETRON HYDROCHLORIDE * LOPERAMIDE FLUTICASONE+VILANTEROL INSULIN NEUTRAL/ISOPHANE	█	█████	█	█	62	F	█████
131014	██████	NOV2018	ANAPHYLACTIC REACTION	* KONSYL D	█	█████	█	█	21	F	█████
131256	██████	DEC2018	RASH ERYTHEMATOUS PRURITUS OEDEMA PERIPHERAL TACHYCARDIA TACHYPNOEA	* CEFUROXIME * ONDANSETRON HYDROCHLORIDE * LOPERAMIDE FLUTICASONE+VILANTEROL INSULIN NEUTRAL/ISOPHANE	█	█████	█	█	62	F	█████

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130633	█	OCT2018	HEPATIC FAILURE	* VILDAGLIPTIN * ALLOPURINOL	█	█	█	█	64	M	█
ATC = Blood and Blood forming organs											
131182	█	DEC2018	HYPOTENSION DIZZINESS	* ALTEPLASE	█	█	█	█	68	M	█
130308	█	OCT2018	EMBOLISM PULMONARY THROMBOSIS VENOUS DEEP MEDICATION ERROR	* DABIGATRAN	█	█		█	54	M	█
130671	█	OCT2018	RECTAL BLEEDING EPISTAXIS RENAL FAILURE ACUTE	* DABIGATRAN * ACETYLSALICYLIC ACID CARVEDILOL ALLOPURINOL SPIRONOLACTONE	█	█	█	█	69	F	█
131282	█	DEC2018	RASH HAEMORRHAGIC	* DABIGATRAN	█	█	█	█	67	M	█
130925	█	NOV2018	DEPRESSION ANGER THINKING ABNORMAL SUICIDAL IDEATION	* RIVAROXABAN	█	█	█	█	64	F	█
130619	█	OCT2018	DRUG INTERACTION MEDICINE INEFFECTIVE	I TICAGRELOR I CARBAMAZEPINE	█	█	█	█	73	M	█
130545	█	OCT2018	ANAPHYLACTIC REACTION	* IRON CARBOXYMALTOSE OXAZEPAM QUETIAPINE AMOXICILLIN/CLAVULANIC ACID THYROXINE	█	█	█	█	67	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
<b>ATC = Cardiovascular</b>											
130889	██████	NOV2018	DERMATITIS FORMICATION	* PROCTOSEDYL	██████				67	F	██████
130580	██████	OCT2018	RASH PUSTULAR LIPS DRY LIPS SWELLING NON-SPECIFIC	* OMEPRAZOLE * DILTIAZEM DABIGATRAN	█	██████	██████	██████	80	F	██████
131008	██████	NOV2018	HEPATITIS JAUNDICE COUGHING DYSPTNOEA NEUTROPENIA	* ATORVASTATIN TICAGRELOR ACE INHIBITOR (NOS)	█	██████	██████	██████	67	F	██████
130897	██████	NOV2018	MYALGIA DEPRESSION SUICIDAL IDEATION CRAMPS SPASM GENERALISED	* PRAVASTATIN CILAZAPRIL FELODIPINE PROPRANOLOL NORTRIPTYLINE	█	██████	██████	██████	50	M	██████
<b>ATC = Dermatological</b>											
130422	██████	OCT2018	ANAPHYLAXIS SKIN TEST POSITIVE ANTIBODIES DRUG SPECIFIC	* SUXAMETHONIUM CHLORIDE * CHLORHEXIDINE FENTANYL PROPOFOL CEFUROXIME	█	██████	██████	██████	54	F	██████
130514	██████	OCT2018	ANAPHYLACTIC REACTION SKIN TEST POSITIVE ALLERGY TEST POSITIVE	* CHLORHEXIDINE ROCURONIUM FENTANYL MIDAZOLAM SEVOFLURANE	█	██████	██████	██████	55	M	██████
131332	██████	DEC2018	NAUSEA TACHYCARDIA HYPOTENSION ANAPHYLAXIS SKIN TEST POSITIVE	* CHLORHEXIDINE SILVER SULFADIAZINE GEN ANAESTHETICS UNCLASSIFIED	█	██████	██████	██████	57	M	██████

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
<b>ATC = Genito Urinary System and Sex Hormones</b>											
131142	██████	DEC2018	THROMBOSIS CEREBRAL	* LEVLEN ED	█		█		41	F	██████
131141	██████	DEC2018	PREGNANCY ECTOPIC MEDICINE INEFFECTIVE	* MIRENA	█	█	█	█	35	F	██████
131145	██████	DEC2018	UTERINE PERFORATION	* MIRENA	█	█	█	█	32	F	██████
131207	██████	DEC2018	HEPATITIS ABDOMINAL PAIN LETHARGY ANOREXIA NAUSEA	* CYPROTERONE ACETATE IBUPROFEN PARACETAMOL	█	█	█	█	44	F	██████
130316	██████	OCT2018	DIZZINESS MEMORY LOSS INSOMNIA ARTHRALGIA	* FINASTERIDE	█	█	█	█	69	M	██████
<b>ATC = Systemic Hormones (excluding Sex Hormones)</b>											
130582	██████	OCT2018	TENDON RUPTURE OEDEMA LEGS LEG PAIN	* PREDNISONE * CEPHAZOLIN * FLUCLOXACILLIN PROBENECID TIOTROPIUM BROMIDE	█	█	█	█	41	M	██████
130589	██████	OCT2018	TREMOR DEPRESSION DIARRHOEA INSOMNIA ANXIETY	* FLUOXETINE * TRAMADOL * PREDNISONE METHOTREXATE HYDROXYCHLOROQUINE	█	█	█	█	45	M	██████
131326	██████	DEC2018	MANIA	* PREDNISONE LITHIUM CARBONATE	█	█	█	█	55	F	██████

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130445	█	OCT2018	ANAPHYLACTIC REACTION	* TRIAMCINOLONE LIGNOCAINE SALBUTAMOL FLUTICASONE/SALMETEROL			█	█	33	M	█
ATC = Anti-infectives											
130423	█	OCT2018	ANAPHYLACTIC REACTION	* AMOXICILLIN/CLAVULANIC ACID	█	█	█	█	64	M	█
130668	█	OCT2018	ANAPHYLACTIC REACTION	* AMOXICILLIN/CLAVULANIC ACID	█	█	█	█	58	F	█
130750	█	NOV2018	ANAPHYLAXIS	* AMOXICILLIN/CLAVULANIC ACID	█	█	█	█	75	M	█
130853	█	NOV2018	ANAPHYLACTIC REACTION	* AMOXICILLIN/CLAVULANIC ACID	█	█	█	█	50	M	█
131071	█	NOV2018	HEPATIC ENZYMES INCREASED	* CEPHAZOLIN * AMOXICILLIN/CLAVULANIC ACID			█	█	43	M	█
131178	█	DEC2018	DYSPNOEA RASH ANGIOEDEMA HYPOTENSION ANAPHYLAXIS	* AMOXICILLIN/CLAVULANIC ACID CODEINE PARACETAMOL NORETHISTERONE IBUPROFEN		█	█	█	35	F	█
131289	█	DEC2018	ANAPHYLACTIC REACTION	* AMOXICILLIN/CLAVULANIC ACID	█	█	█	█	66	F	█
130297	█	OCT2018	STEVENS JOHNSON SYNDROME	* COTRIMOXAZOLE * FLUCLOXACILLIN * IBUPROFEN CODEINE PARACETAMOL		█	█	█	34	F	█



REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130582	█	OCT2018	TENDON RUPTURE OEDEMA LEGS LEG PAIN	* PREDNISONE * CEPHAZOLIN * FLUCLOXACILLIN PROBENECID TIOTROPIUM BROMIDE	█	█	█	█	41	M	█
130801	█	NOV2018	URTICARIA MYALGIA ARTHRALGIA SWELLING LOCALISED	* FLUCLOXACILLIN ERYTHROMYCIN	█	█	█	█	23	M	█
130586	█	OCT2018	ANAPHYLACTIC REACTION	* PIPERACILLIN/TAZOBACTAM * GEN ANAESTHETICS MULTIPLE ATORVASTATIN ACETYLSALICYLIC ACID GABAPENTIN	█	█	█	█	46	F	█
131256	█	DEC2018	RASH ERYTHEMATOUS PRURITUS OEDEMA PERIPHERAL TACHYCARDIA TACHYPNOEA	* CEFUROXIME * ONDANSETRON HYDROCHLORIDE * LOPERAMIDE FLUTICASONE+VILANTEROL INSULIN NEUTRAL/ISOPHANE	█	█	█	█	62	F	█
130803	█	NOV2018	RASH MACULO-PAPULAR	* CEPHALEXIN	█	█	█	█	79	M	█
130382	█	OCT2018	ANAPHYLACTIC REACTION SKIN TEST POSITIVE	* CEPHAZOLIN	█		█	█	43	F	█
130582	█	OCT2018	TENDON RUPTURE OEDEMA LEGS LEG PAIN	* PREDNISONE * CEPHAZOLIN * FLUCLOXACILLIN PROBENECID TIOTROPIUM BROMIDE	█	█	█	█	41	M	█
130674	█	OCT2018	SKIN TEST POSITIVE ANAPHYLAXIS	* CEPHAZOLIN MIDAZOLAM FENTANYL ROCURONIUM PARECOXIB	█	█	█	█	21	M	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130675	█	OCT2018	ANAPHYLACTIC REACTION SKIN TEST POSITIVE	* CEPHAZOLIN MIDAZOLAM FENTANYL ATRACURIUM CHLORHEXIDINE	█	█	█	█	48	F	█
130676	█	OCT2018	ANGIOEDEMA SNEEZING EXCESSIVE VOMITING SKIN TEST NEGATIVE	* CEPHAZOLIN CHLORHEXIDINE BUPIVACAINE FENTANYL MORPHINE SULPHATE	█	█	█	█	34	F	█
130677	█	OCT2018	MACULAR RASH HYPOTENSION FLUSHING NAUSEA	* BUPIVACAINE * CEPHAZOLIN FENTANYL MORPHINE SULPHATE OXYTOCIN	█	█	█	█	35	F	█
130965	█	NOV2018	ANAPHYLACTIC REACTION	* CEPHAZOLIN	█	█	█	█	30	F	█
131029	█	NOV2018	ANAPHYLACTIC REACTION SKIN TEST POSITIVE	* CEPHAZOLIN FENTANYL PROPOFOL PRILOCAINE CHLORHEXIDINE	█	█	█	█	39	M	█
131071	█	NOV2018	HEPATIC ENZYMES INCREASED	* CEPHAZOLIN * AMOXICILLIN/CLAVULANIC ACID	█	█	█	█	43	M	█
131170	█	DEC2018	OXYGEN SATURATION DECREASED HYPOTENSION RASH ANAPHYLAXIS SKIN TEST POSITIVE	* CEPHAZOLIN FENTANYL MIDAZOLAM	█	█	█	█	57	M	█
131186	█	DEC2018	URTICARIA BRONCHOSPASM SKIN TEST POSITIVE	* CEPHAZOLIN GEN ANAESTHETICS MULTIPLE	█	█	█	█	49	M	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
131070	█	NOV2018	EOSINOPHILIA NEUTROPENIA FEVER	* MEROPENEM	█		█	█	70	M	█
130297	█	OCT2018	STEVENS JOHNSON SYNDROME	* COTRIMOXAZOLE * FLUCLOXACILLIN * IBUPROFEN CODEINE PARACETAMOL	█	█	█	█	34	F	█
130443	█	OCT2018	TOXIC EPIDERMAL NECROLYSIS	* COTRIMOXAZOLE	█	█	█	█	26	F	█
130498	█	OCT2018	ANAPHYLACTIC REACTION	* COTRIMOXAZOLE	█	█	█	█	50	F	█
130776	█	NOV2018	A. G. EXANTHEMATOUS PUSTULOSIS	* BENDAMUSTINE * RITUXIMAB * COTRIMOXAZOLE VALACICLOVIR	█	█	█	█	60	F	█
130960	█	NOV2018	TONGUE SWELLING NON-SPECIFIC FEELING COLD SHIVERING DIZZINESS	* TRIMETHOPRIM	█	█	█	█	73	F	█
131131	█	DEC2018	DRESS SYNDROME	* TRIMETHOPRIM DOXAZOSIN THYROXINE	█	█	█	█	61	M	█
130920	█	NOV2018	WEAKNESS GENERALIZED EXHAUSTION	* CIPROFLOXACIN POTASSIUM CHLORIDE	█	█	█	█	70	M	█
131017	█	NOV2018	NEPHRITIS INTERSTITIAL	* NITROFURANTOIN METHYLPREDNISOLONE ACETATE DAIVOBET 50/500 FELODIPINE	█	█	█	█	66	M	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130687	██████	NOV2018	RASH FEVER PANCYTOPENIA HEPATIC ENZYMES INCREASED	* TEICOPLANIN	█	██████	██████	██████	59	F	██████
131291	██████	DEC2018	THROAT IRRITATION	* VANCOMYCIN	█	██████	██████	██████	32	F	██████
130692	██████	NOV2018	HEPATITIS NAUSEA JAUNDICE	* ISONIAZID * PANTOPRAZOLE CABERGOLINE PARACETAMOL PYRIDOXINE	█	██████	██████	██████	64	M	██████
130569	██████	OCT2018	ARM PAIN	* INFLUENZA - QUADRIVALENT	█	██████	██████	██████	76	F	██████
131057	██████	NOV2018	HERPES ZOSTER INFECTION SECONDARY ARM PAIN FEELING HOT AND COLD	* VARICELLA VACCINE - SHINGLES DABIGATRAN AMIODARONE	█	██████	██████	██████	77	M	██████

ATC = Antineoplastics and Immunomodulating Agents

130776	██████	NOV2018	A. G. EXANTHEMATOUS PUSTULOSIS	* BENDAMUSTINE * RITUXIMAB * COTRIMOXAZOLE VALACICLOVIR	█	██████	██████	██████	60	F	██████
131140	██████	DEC2018	MUCOSITIS NOS MEDICAL DEVICE COMPLICATION DRUG ADMINISTRATION RATE RXN	* FLUOROURACIL	█	██████	██████	██████	78	F	██████
131179	██████	DEC2018	EPISTAXIS THROMBOCYTOPENIA PANCYTOPENIA GOUT AGGRAVATED FEELING UNWELL	* METHOTREXATE FOLIC ACID AMLODIPINE	█	██████	██████	██████	69	F	██████

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130616	█	OCT2018	RASH ACNEIFORM CELLULITIS	* CETUXIMAB ENSURE	█	█	█	█	69	M	█
130776	█	NOV2018	A. G. EXANTHEMATOUS PUSTULOSIS	* BENDAMUSTINE * RITUXIMAB * COTRIMOXAZOLE VALACICLOVIR	█	█	█	█	60	F	█
131322	█	DEC2018	SUICIDAL IDEATION AGGRESSIVE REACTION	* GOSERELIN ACETATE ZINC NOS	█	█	█	█	51	F	█
130849	█	NOV2018	CONJUNCTIVITIS ARTHRITIS	* BCG IMMUNOTHERAPY HYDROXYCHLOROQUINE SALBUTAMOL FLUTICASONE/SALMETEROL DILTIAZEM	█	█	█	█	74	F	█
130348	█	OCT2018	LOWER RESP TRACT INFECTION	* ADALIMUMAB	█	█	█	█	29	M	█
130353	█	OCT2018	ANAPHYLAXIS ANTIBODIES DRUG SPECIFIC	* NATALIZUMAB	█	█	█	█	49	F	█
ATC = Musculoskeletal											
130666	█	OCT2018	ANAPHYLAXIS	* DICLOFENAC	█	█	█	█	75	M	█
131260	█	DEC2018	ANAPHYLACTIC REACTION	* DICLOFENAC MAGNESIUM CILAZAPRIL	█	█	█	█	49	F	█
130297	█	OCT2018	STEVENS JOHNSON SYNDROME	* COTRIMOXAZOLE * FLUCLOXACILLIN * IBUPROFEN CODEINE PARACETAMOL	█	█	█	█	34	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130503	█	OCT2018	BRONCHOSPASM HYPOTENSION	* IBUPROFEN SALBUTAMOL ALCOHOL (ETHYL)	█	█	█	█	61	M	█
130771	█	NOV2018	GI HAEMORRHAGE MEDICATION ERROR	* NAPROXEN GABAPENTIN ATORVASTATIN AMITRIPTYLINE FLUOXETINE	█	█	█	█	56	F	█
131030	█	NOV2018	ANAPHYLACTIC REACTION SKIN TEST POSITIVE	* PANCURONIUM MIDAZOLAM FENTANYL PROPOFOL CHLORHEXIDINE	█	█	█	█	75	F	█
131187	█	DEC2018	ANAPHYLACTIC REACTION SKIN TEST POSITIVE	* ROCURONIUM PANCURONIUM SUXAMETHONIUM CHLORIDE GEN ANAESTHETICS MULTIPLE	█		█	█	45	F	█
130422	█	OCT2018	ANAPHYLAXIS SKIN TEST POSITIVE ANTIBODIES DRUG SPECIFIC	* SUXAMETHONIUM CHLORIDE * CHLORHEXIDINE FENTANYL PROPOFOL CEFUROXIME	█	█	█	█	54	F	█
130427	█	OCT2018	ANAPHYLACTIC REACTION SKIN TEST NEGATIVE	* SUXAMETHONIUM CHLORIDE FENTANYL PROPOFOL	█	█	█	█	58	F	█
130633	█	OCT2018	HEPATIC FAILURE	* VILDAGLIPTIN * ALLOPURINOL	█	█	█	█	64	M	█
131099	█	DEC2018	LOWER RESP TRACT INFECTION	* DENOSUMAB	█	█	█	█	68	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130501	█	OCT2018	FEVER CONFUSION LEUKOCYTOSIS	* ZOLEDRONATE LETROZOLE FRUSEMIDE METFORMIN ATORVASTATIN	█	█	█	█	76	F	█
ATC = Nervous System											
131185	█	DEC2018	HYPOTENSION BRONCHOSPASM SKIN TEST POSITIVE	* KETAMINE PATENT BLUE V GEN ANAESTHETICS MULTIPLE	█	█	█	█	60	F	█
130677	█	OCT2018	MACULAR RASH HYPOTENSION FLUSHING NAUSEA	* BUPIVACAINE * CEPHAZOLIN FENTANYL MORPHINE SULPHATE OXYTOCIN	█	█	█	█	35	F	█
131171	█	DEC2018	ANAPHYLAXIS THROAT SWELLING NON-SPECIFIC ANGIOEDEMA NASAL CONGESTION URTICARIA	* LIGNOCAINE CHLORHEXIDINE	█	█	█	█	45	F	█
130777	█	NOV2018	MOUTH DRY TOOTH CARIES	* OXYCODONE * GABAPENTIN TRAMADOL CODEINE IBUPROFEN	█	█	█	█	59	F	█
130589	█	OCT2018	TREMOR DEPRESSION DIARRHOEA INSOMNIA ANXIETY	* FLUOXETINE * TRAMADOL * PREDNISONE METHOTREXATE HYDROXYCHLOROQUINE	█	█	█	█	45	M	█
130671	█	OCT2018	RECTAL BLEEDING EPISTAXIS RENAL FAILURE ACUTE	* DABIGATRAN * ACETYLSALICYLIC ACID CARVEDILOL ALLOPURINOL SPIRONOLACTONE	█	█	█	█	69	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
131244	█	DEC2018	ANGIOEDEMA	* ACETYSALICYLIC ACID CANDESARTAN ATORVASTATIN OMEPRAZOLE TICAGRELOR	█	█	█	█	65	M	█
130499	█	OCT2018	VOICE ALTERATION THROAT TIGHTNESS BRONCHOSPASM RASH	* PARACETAMOL GLUCOSAMINE + CHONDROITIN	█	█	█	█	54	M	█
130935	█	NOV2018	ANAPHYLACTIC REACTION	* PARACETAMOL	█	█	█	█	34	M	█
130619	█	OCT2018	DRUG INTERACTION MEDICINE INEFFECTIVE	I TICAGRELOR I CARBAMAZEPINE	█	█	█	█	73	M	█
130777	█	NOV2018	MOUTH DRY TOOTH CARIES	* OXYCODONE * GABAPENTIN TRAMADOL CODEINE IBUPROFEN	█	█	█	█	59	F	█
130646	█	OCT2018	THROAT SWELLING NON-SPECIFIC TONGUE SWELLING NON-SPECIFIC MUSCLE WEAKNESS SPEECH DISORDER MALAISE	* PREGABALIN	█	█	█	█	75	F	█
130319	█	OCT2018	QT PROLONGED	* CLOZAPINE	█	█	█	█	42	M	█
130493	█	OCT2018	MYOCARDITIS TROPONIN T INCREASED EOSINOPHILIA	* CLOZAPINE CILAZAPRIL METFORMIN SIMVASTATIN DABIGATRAN	█	█	█	█	49	M	█
130807	█	NOV2018	SCHIZOPHRENIC REACTION	* CLOZAPINE	█	█	█	█	53	F	█



REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
131319	█	DEC2018	TROPONIN T INCREASED C-REACTIVE PROTEIN POSITIVE MYOCARDITIS	* CLOZAPINE BENZTROPINE MESYLATE TOPIRAMATE CILAZAPRIL AMISULPRIDE	█	█	█	█	54	F	█
131318	█	DEC2018	DYSKINESIA HYPOKALAEMIA CREATINE PHOSPHOKINASE INCREASED ARRHYTHMIA HYPERTONIA	* CLOZAPINE	█		█	█	54	M	█
130440	█	OCT2018	RENAL IMPAIRMENT LITHIUM TOXICITY DROWSINESS DEHYDRATION	* LITHIUM CARBONATE VENLAFAXINE MIRTAZAPINE OLANZAPINE	█	█		█	77	F	█
130313	█	OCT2018	POST INJECTION SYNDROME	* OLANZAPINE	█				60	M	█
131147	█	DEC2018	POST INJECTION SYNDROME	* OLANZAPINE VENLAFAXINE	█	█	█	█	41	M	█
131313	█	DEC2018	POST INJECTION SYNDROME	* OLANZAPINE INSULIN METFORMIN LOSARTAN ATORVASTATIN	█	█	█	█	63	M	█
130315	█	OCT2018	EMBOLISM PULMONARY	* PALIPERIDONE	█	█			35	M	█
130589	█	OCT2018	TREMOR DEPRESSION DIARRHOEA INSOMNIA ANXIETY	* FLUOXETINE * TRAMADOL * PREDNISONE METHOTREXATE HYDROXYCHLOROQUINE	█	█	█	█	45	M	█
131243	█	DEC2018	SUICIDE ATTEMPT	* PAROXETINE	█	█		█	41	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130549	█	OCT2018	TINNITUS	* SERTRALINE	█	█	█	█	58	F	█
130216	█	OCT2018	PARONIRIA AMNESIA SUICIDAL IDEATION NERVOUSNESS TEETH-GRINDING	* VENLAFAXINE AMITRIPTYLINE LORAZEPAM	█	█	█	█	53	M	█
130218	█	OCT2018	IRRITABILITY SUICIDAL IDEATION FATIGUE BRAND SWITCH HEADACHE	* VENLAFAXINE	█	█	█	█	36	F	█
130222	█	OCT2018	THERAPEUTIC RESPONSE DECREASED BRAND SWITCH SUICIDE ATTEMPT	* VENLAFAXINE	█	█	█		53	F	█
130223	█	OCT2018	WEIGHT INCREASE MOUTH DRY THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION BRAND SWITCH	* VENLAFAXINE	█	█	█	█	35	F	█
130230	█	OCT2018	SUICIDAL IDEATION ANGER DYSPRAXIA CONFUSION	* VENLAFAXINE	█	█	█		36	F	█
130232	█	OCT2018	THERAPEUTIC RESPONSE DECREASED BRAND SWITCH LETHARGY SUICIDAL IDEATION PARONIRIA	* VENLAFAXINE ZINC NOS BUPROPION HYDROCHLORIDE OMEPRAZOLE	█	█	█	█	43	F	█
130235	█	OCT2018	JUDGEMENT IMPAIRED THERAPEUTIC RESPONSE DECREASED DEPERSONALIZATION SUICIDE ATTEMPT	* VENLAFAXINE	█	█	█	█	39	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130236	█	OCT2018	THERAPEUTIC RESPONSE DECREASED SUICIDE ATTEMPT PSYCHOSIS	* VENLAFAXINE	█	█	█	█	43	F	█
130239	█	OCT2018	NAUSEA HEADACHE CONFUSION VOMITING THINKING ABNORMAL	* VENLAFAXINE	█	█	█	█	51	F	█
130242	█	OCT2018	NAUSEA HEADACHE THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION INTENTIONAL OVERDOSE	* VENLAFAXINE MIRTAZAPINE	█	█	█	█	22	F	█
130244	█	OCT2018	JITTERINESS THERAPEUTIC RESPONSE DECREASED FUZZY HEAD THINKING ABNORMAL SUICIDAL IDEATION	* VENLAFAXINE ATENOLOL	█	█	█	█	35	F	█
130263	█	OCT2018	MIGRAINE HEADACHE THERAPEUTIC RESPONSE DECREASED MUSCULOSKELETAL PAIN BRAND SWITCH	* VENLAFAXINE	█	█	█	█	29	F	█
130264	█	OCT2018	THERAPEUTIC RESPONSE DECREASED BRAND SWITCH SUICIDAL IDEATION THOUGHTS OF SELF HARM	* VENLAFAXINE NORTRIPTYLINE ZOPICLONE PANTOPRAZOLE IBUPROFEN	█	█	█	█	50	F	█
130265	█	OCT2018	AGGRESSIVE REACTION PSYCHOSIS BRAND SWITCH	* VENLAFAXINE GABAPENTIN ATORVASTATIN	█	█	█	█	60	M	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130267	█	OCT2018	THERAPEUTIC RESPONSE DECREASED PARONIRIA TIREDNESS NIGHT SWEATS SUICIDAL IDEATION	* VENLAFAXINE	█	█	█	█	43	F	█
130268	█	OCT2018	THERAPEUTIC RESPONSE DECREASED BRAND SWITCH SUICIDAL IDEATION PARONIRIA	* VENLAFAXINE TOPIRAMATE HYDROXYCHLOROQUINE BISOPROLOL METHOTREXATE	█	█	█	█	55	F	█
130269	█	OCT2018	SUICIDAL IDEATION THERAPEUTIC RESPONSE DECREASED BRAND SWITCH HYPERTENSION	* VENLAFAXINE	█	█	█	█	28	M	█
130270	█	OCT2018	THERAPEUTIC RESPONSE DECREASED VERTIGO SUICIDAL IDEATION SWEATING INCREASED ANGER	* VENLAFAXINE	█	█	█	█	27	F	█
130271	█	OCT2018	THERAPEUTIC RESPONSE DECREASED BRAND SWITCH SUICIDAL IDEATION	* VENLAFAXINE PARACETAMOL AMITRIPTYLINE	█	█	█	█	32	F	█
130274	█	OCT2018	ELECTRIC SHOCK SENSATION TWITCHING HEADACHE THERAPEUTIC RESPONSE DECREASED SUICIDE ATTEMPT	* VENLAFAXINE	█	█	█	█	25	M	█
130276	█	OCT2018	DRUG WITHDRAWAL SYNDROME BRAND SWITCH THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION SELF INJURY	* VENLAFAXINE	█	█	█	█	36	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130277	█	OCT2018	THERAPEUTIC RESPONSE DECREASED HEADACHE SLEEP DISTURBED CONCENTRATION IMPAIRED SELF INJURY	* VENLAFAXINE ATORVASTATIN	█	█	█	█	28	F	█
130282	█	OCT2018	DIZZINESS MOOD SWINGS VISION ABNORMAL NAUSEA BRAND SWITCH	* VENLAFAXINE QUETIAPINE	█	█	█	█	44	F	█
130284	█	OCT2018	INSOMNIA EXHAUSTION DEPRESSION LETHARGY WEIGHT INCREASE	* VENLAFAXINE	█	█	█	█	44	F	█
130286	█	OCT2018	PARONIRIA SWEATING INCREASED SUICIDAL IDEATION ANGER FATIGUE	* VENLAFAXINE	█	█	█	█	62	F	█
130288	█	OCT2018	THERAPEUTIC RESPONSE DECREASED BRAND SWITCH ANGER THOUGHTS OF SELF HARM PARANOID REACTION	* VENLAFAXINE QUETIAPINE METFORMIN SPIRONOLACTONE GABAPENTIN	█	█	█	█	33	F	█
130289	█	OCT2018	ANXIETY APPETITE DECREASED INSOMNIA SUICIDAL IDEATION	* VENLAFAXINE	█	█	█	█	49	F	█
130292	█	OCT2018	THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION SELF INJURY IRRITABILITY ANGER	* VENLAFAXINE	█	█	█	█	38	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130303	█	OCT2018	THERAPEUTIC RESPONSE DECREASED NAUSEA HEADACHE CONSTIPATION ANXIETY	* VENLAFAXINE ZOPICLONE CLONAZEPAM QUETIAPINE OMEPRAZOLE	█	█	█	█	43	F	█
130341	█	OCT2018	SUICIDAL IDEATION DEPERSONALIZATION NIGHT SWEATS	* VENLAFAXINE	█				25	F	█
130347	█	OCT2018	THERAPEUTIC RESPONSE DECREASED PALPITATION SUICIDAL IDEATION APPETITE DECREASED PSORIASIS AGGRAVATED	* VENLAFAXINE	█	█	█	█	56	F	█
130396	█	OCT2018	SUICIDAL IDEATION SUICIDE ATTEMPT THERAPEUTIC RESPONSE DECREASED	* VENLAFAXINE	█	█	█	█	53	F	█
130402	█	OCT2018	NIGHT SWEATS FUZZY HEAD THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION	* VENLAFAXINE	█	█	█	█	40	F	█
130403	█	OCT2018	THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION	* VENLAFAXINE	█	█	█	█	45	F	█
130408	█	OCT2018	BLOATING CONSTIPATION	* VENLAFAXINE	█	█	█	█	23	F	█
130416	█	OCT2018	THERAPEUTIC RESPONSE DECREASED TACHYCARDIA CHEST DISCOMFORT PAIN	* VENLAFAXINE	█	█	█	█	38	F	█
130420	█	OCT2018	THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION THOUGHTS OF SELF HARM ELECTRIC SHOCK SENSATION	* VENLAFAXINE VALPROATE SODIUM LITHIUM CARBONATE ZOPICLONE LORAZEPAM	█	█	█	█	42	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130421	█	OCT2018	THERAPEUTIC RESPONSE DECREASED SUICIDE ATTEMPT SUICIDAL IDEATION	* VENLAFAXINE	█	█	█	█	54	F	█
130451	█	OCT2018	THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION	* VENLAFAXINE	█	█	█	█	20	F	█
130452	█	OCT2018	SLEEP DISTURBED PARAESTHESIA LIPS HEADACHE SUICIDAL IDEATION	* VENLAFAXINE	█	█	█	█	40	M	█
130454	█	OCT2018	THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION PALPITATION	* VENLAFAXINE BUPROPION HYDROCHLORIDE PROGYNOVA ACETYLSALICYLIC ACID	█	█	█	█	51	F	█
130457	█	OCT2018	SUICIDAL IDEATION THERAPEUTIC RESPONSE DECREASED ANGER THINKING ABNORMAL	* VENLAFAXINE SALBUTAMOL	█	█	█	█	38	F	█
130460	█	OCT2018	SUICIDAL IDEATION THERAPEUTIC RESPONSE DECREASED FUZZY HEAD FATIGUE	* VENLAFAXINE	█				49	F	█
130462	█	OCT2018	SUICIDAL IDEATION SLEEP DISTURBED FUZZY HEAD CONCENTRATION IMPAIRED	* VENLAFAXINE	█	█	█	█	29	M	█
130464	█	OCT2018	SUICIDAL IDEATION WEIGHT INCREASE FATIGUE AGGRESSIVE REACTION SEROTONIN SYNDROME	* VENLAFAXINE VALPROATE SODIUM	█	█	█	█	29	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130468	█	OCT2018	NIGHT SWEATS VISION DECREASED MIGRAINE PARONIRIA SLEEP DISTURBED	* VENLAFAXINE	█	█	█	█	46	F	█
130473	█	OCT2018	MEDICINE INEFFECTIVE NIGHT SWEATS SUICIDAL IDEATION ANGER WEIGHT INCREASE	* VENLAFAXINE	█	█	█	█	47	F	█
130479	█	OCT2018	NIGHT SWEATS TEETH-GRINDING SHAKING LETHARGY THERAPEUTIC RESPONSE DECREASED	* VENLAFAXINE	█	█	█	█	44	M	█
130480	█	OCT2018	THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION SWEATING INCREASED WEIGHT INCREASE LETHARGY	* VENLAFAXINE	█	█	█	█	45	F	█
130509	█	OCT2018	THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION	* VENLAFAXINE QUETIAPINE LORAZEPAM MIRENA	█	█	█	█	23	F	█
130510	█	OCT2018	THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION MYALGIA WEIGHT INCREASE PAIN INFLAMMATION ACTIVATED	* VENLAFAXINE	█	█	█	█	69	F	█
130603	█	OCT2018	THERAPEUTIC RESPONSE DECREASED IRRITABILITY CHARACTER CHANGE DEPERSONALIZATION MEMORY IMPAIRMENT	* VENLAFAXINE	█	█	█	█	44	F	█



REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130604	█	OCT2018	WEIGHT INCREASE DIZZINESS TINNITUS CRAMP ABDOMINAL MYALGIA	* VENLAFAXINE	█	█	█	█	39	F	█
130605	█	OCT2018	DIZZINESS SHAKING THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION INSOMNIA	* VENLAFAXINE ATORVASTATIN METOPROLOL OMEPRAZOLE ZOPICLONE	█	█	█	█	52	F	█
130624	█	OCT2018	THERAPEUTIC RESPONSE DECREASED HYPERTENSION EXHAUSTION MYALGIA ARTHRALGIA	* VENLAFAXINE ZOPICLONE	█	█	█	█	65	F	█
130625	█	OCT2018	THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION	* VENLAFAXINE CHLORTHALIDONE AMITRIPTYLINE DOMPERIDONE EZETIMIBE	█	█	█	█	56	F	█
130635	█	OCT2018	THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION	* VENLAFAXINE	█			█	50	F	█
130637	█	OCT2018	THERAPEUTIC RESPONSE DECREASED NAUSEA SELF INJURY FATIGUE MEMORY DISTURBANCE	* VENLAFAXINE	█	█	█	█	33	F	█
130638	█	OCT2018	THERAPEUTIC RESPONSE DECREASED HEADACHE TINNITUS	* VENLAFAXINE	█	█	█	█	56	M	█
130655	█	OCT2018	SUICIDAL IDEATION COGNITIVE FUNCTION ABNORMAL TIREDNESS LETHARGY	* VENLAFAXINE BUDESONIDE/EFORMOTEROL	█	█	█	█	37	M	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130716	█	NOV2018	THERAPEUTIC RESPONSE DECREASED SELF INJURY CONCENTRATION IMPAIRED MIGRAINE PARONIRIA	* VENLAFAXINE	█	█	█	█	37	F	█
130717	█	NOV2018	THERAPEUTIC RESPONSE DECREASED PALPITATION NAUSEA SUICIDAL IDEATION SELF INJURY	* VENLAFAXINE SALBUTAMOL	█	█	█	█	29	F	█
130722	█	NOV2018	LETHARGY FATIGUE THERAPEUTIC RESPONSE DECREASED OEDEMA MEMORY DISTURBANCE	* VENLAFAXINE QUETIAPINE	█	█	█	█	53	F	█
130723	█	NOV2018	THERAPEUTIC RESPONSE DECREASED MUSCULOSKELETAL PAIN ARTHRALGIA LETHARGY MIGRAINE	* VENLAFAXINE QUETIAPINE	█	█	█	█	22	F	█
130724	█	NOV2018	SUICIDAL IDEATION WEIGHT INCREASE ANXIETY	* VENLAFAXINE NORTRIPTYLINE RANITIDINE LORATADINE	█	█	█	█	47	F	█
130757	█	NOV2018	THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION IRRITABILITY INSOMNIA	* VENLAFAXINE GABAPENTIN	█	█	█	█	33	F	█
130838	█	NOV2018	THERAPEUTIC RESPONSE DECREASED PARONIRIA INSOMNIA SWEATING INCREASED SHAKING	* VENLAFAXINE MAGNESIUM VITAMIN B COMPLEX AMITRIPTYLINE	█	█	█	█	35	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
130859	█	NOV2018	THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION	* VENLAFAXINE BENDROFLUAZIDE CYPROTERONE ACETATE ESTRADOT QUETIAPINE	█	█	█	█	50	F	█
130900	█	NOV2018	THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION	* VENLAFAXINE ZOPICLONE SALBUTAMOL	█	█	█	█	31	F	█
130966	█	NOV2018	NAUSEA TIREDNESS DROWSINESS SLEEP DISTURBED APPETITE DECREASED	* VENLAFAXINE	█	█	█	█	36	M	█
130981	█	NOV2018	THERAPEUTIC RESPONSE DECREASED ANGER SUICIDAL IDEATION HEADACHE NAUSEA	* VENLAFAXINE	█	█	█	█	29	F	█
130982	█	NOV2018	WEAKNESS GENERALIZED THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION OBSESSIONAL NEUROSIS INSOMNIA	* VENLAFAXINE THYROXINE	█	█	█	█	41	F	█
131021	█	NOV2018	SUICIDAL IDEATION ANGER INSOMNIA SUICIDE ATTEMPT PARANOID REACTION	* VENLAFAXINE METFORMIN CANDESARTAN DILTIAZEM THYROXINE	█	█	█	█	57	M	█
131051	█	NOV2018	ANGER DEPRESSION SUICIDAL IDEATION EMOTIONAL LABILITY THERAPEUTIC RESPONSE DECREASED	* VENLAFAXINE	█	█	█	█	58	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
131105	█	DEC2018	INSOMNIA HYPERAESTHESIA SUICIDE ATTEMPT PERSONALITY DISORDER THERAPEUTIC RESPONSE DECREASED	* VENLAFAXINE	█	█	█	█	68	F	█
131106	█	DEC2018	TEARFUL ANGER LETHARGY THERAPEUTIC RESPONSE DECREASED SUICIDAL IDEATION	* VENLAFAXINE AMLODIPINE BENDROFLUAZIDE OMEPRAZOLE ZOPICLONE	█	█	█	█	52	F	█
131124	█	DEC2018	DEPERSONALIZATION SUICIDAL IDEATION THERAPEUTIC RESPONSE DECREASED COGNITIVE FUNCTION ABNORMAL AGGRESSIVE REACTION	* VENLAFAXINE	█		█	█	56	M	█
131213	█	DEC2018	ANXIETY MOOD DISORDER SUICIDE ATTEMPT THERAPEUTIC RESPONSE DECREASED	* VENLAFAXINE	█	█	█	█	42	F	█
131214	█	DEC2018	THERAPEUTIC RESPONSE DECREASED ANGER SUICIDAL IDEATION SOMNOLENCE LETHARGY	* VENLAFAXINE	█	█	█	█	42	M	█
131247	█	DEC2018	HEADACHE SUICIDAL IDEATION SELF INJURY FATIGUE PARONIRIA	* VENLAFAXINE DIAZEPAM LORAZEPAM ZOPICLONE GABAPENTIN	█	█	█	█	54	F	█

REPORT	ORIGIN	DATE	REACTIONS	DRUGS	ROUTE	DOSE/UNIT	BEGAN	ENDED	AGE	SEX	Ethnicity / OUTCOME
ATC = Respiratory											
130876	█	NOV2018	DEPRESSION SUICIDAL IDEATION ANGER SELF INJURY	* MONTELUKAST SODIUM Cannabis MAGNESIUM	█	█	█	█	38	F	█
130936	█	NOV2018	URTICARIA THROAT TIGHTNESS ANGIOEDEMA FAINTNESS	* GEES LINCTUS	█	█	█	█	57	M	█
ATC = Miscellaneous											
130508	█	OCT2018	ANAPHYLACTIC REACTION SKIN TEST POSITIVE	* PATENT BLUE V MIDAZOLAM FENTANYL PROPOFOL ROCURONIUM	█	█	█	█	38	F	█
131138	█	DEC2018	ANAPHYLAXIS SKIN TEST POSITIVE	* PATENT BLUE V FENTANYL PROPOFOL GLYCOPYRRONIUM BROMIDE CEPHAZOLIN	█	█	█	█	77	F	█
131139	█	DEC2018	SKIN TEST POSITIVE ANAPHYLAXIS	* PATENT BLUE V MIDAZOLAM FENTANYL PROPOFOL CEPHAZOLIN	█	█	█	█	47	F	█